Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia

Clinical Nutrition

Volumn 29, Issue 6, 2010, Pages 733-737

  Busquets, Sílvia ^a   Serpe, Roberto ^b   Sirisi, Sónia ^a   Toledo, Míriam ^a   Coutinho, Joana ^a   Martínez, Raquel ^a   Orpí, Marcel ^a   López Soriano, Francisco J ^a   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cancer cachexia; Megestrol acetate; Muscle force; Physical activity; Skeletal muscle

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATROGIN 1; MEGESTROL ACETATE; MESSENGER RNA; MUSCLE PROTEIN; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; ASCITES HEPATOMA; CACHEXIA; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; GRIP STRENGTH; MALE; MUSCLE ATROPHY; MUSCLE FORCE; MUSCLE MASS; NONHUMAN; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; PROTEIN DEGRADATION; PROTEIN METABOLISM; QUALITY OF LIFE; RAT; SKELETAL MUSCLE; WEIGHT REDUCTION;

ANIMALS; ANOREXIA; APPETITE; BODY WEIGHT; CACHEXIA; ENDOPEPTIDASES; INFLAMMATION; MALE; MEGESTROL ACETATE; MOTOR ACTIVITY; MUSCLE PROTEINS; MUSCULAR ATROPHY; NEOPLASMS; RATS; RATS, WISTAR;

EID: 78649900645     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.06.003     Document Type: Article

References (39)

1. Evans W.J., Morley J.E., Argiles J., Bales C., Baracos V., Guttridge D., et al. Cachexia: a new definition. Clin Nutr 2008, 27:793-799.
2. Argiles J.M., Alvarez B., Lopez-Soriano F.J. The metabolic basis of cancer cachexia. Med Res Rev 1997, 17:477-498.
3. Argiles J.M., Lopez-Soriano F.J. Why do cancer cells have such a high glycolytic rate?. Med Hypotheses 1990, 32:151-155.
4. Ng E.H., Lowry S.F. Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 1991, 5:161-184.
5. Llovera M., Garcia-Martinez C., Lopez-Soriano J., Agell N., Lopez-Soriano F.J., Garcia I., et al. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett 1998, 130:19-27.
6. Llovera M., Garcia-Martinez C., Lopez-Soriano J., Carbo N., Agell N., Lopez-Soriano F.J., et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998, 142:183-189.
7. Argiles J.M., Busquets S., Lopez-Soriano F.J. Metabolic interrelationships between liver and skeletal muscle in pathological states. Life Sci 2001, 69:1345-1361.
8. Warren S. The inmediate cause of death in cancer. Am J Med Sci 1932, 184:610-613.
9. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980, 69:491-497.
10. Loprinzi C.L., Michalak J.C., Schaid D.J., Mailliard J.A., Athmann L.M., Goldberg R.M., et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993, 11:762-767.
11. Bruera E., Macmillan K., Kuehn N., Hanson J., MacDonald R.N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990, 66:1279-1282.
12. Neri B., Garosi V.L., Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 1997, 8:459-465.
13. McCarthy H.D., Crowder R.E., Dryden S., Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994, 265:99-102.
14. Mantovani G., Maccio A., Esu S., Lai P., Santona M.C., Massa E., et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997, 33:602-607.
15. Von Roenn J.H., Armstrong D., Kotler D.P., Cohn D.L., Klimas N.G., Tchekmedyian N.S., et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121:393-399.
16. Loprinzi C.L., Schaid D.J., Dose A.M., Burnham N.L., Jensen M.D. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993, 11:152-154.
17. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res 1997, 17:657-662.
18. Beck S.A., Tisdale M.J. Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer 1990, 62:420-424.
19. Tomiska M., Tomiskova M., Salajka F., Adam Z., Vorlicek J. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003, 50:227-233.
20. Tessitore L., Costelli P., Bonetti G., Baccino F.M. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 1993, 306:52-58.
21. Chomczynski P. NS. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987, 162:156-159.
22. Busquets S., Alvarez B., Lopez-Soriano F.J., Argiles J.M. Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states?. J Cell Physiol 2002, 191:283-289.
23. Llovera M., Garcia-Martinez C., Agell N., Lopez-Soriano F.J., Argiles J.M. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 1997, 230:238-241.
24. Waalkes T.P., Udenfriend S. A fluorimetric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Med 1957, 50:733-736.
25. Sinis N., Guntinas-Lichius O., Irintchev A., Skouras E., Kuerten S., Pavlov S.P., et al. Manual stimulation of forearm muscles does not improve recovery of motor function after injury to a mixed peripheral nerve. Exp Brain Res 2008, 185:469-483.
26. Zangarelli A., Chanseaume E., Morio B., Brugere C., Mosoni L., Rousset P., et al. Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondria-mediated pathway. FASEB J 2006, 20:2439-2450.
27. Busquets S., Figueras M.T., Fuster G., Almendro V., Moore-Carrasco R., Ametller E., et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004, 64:6725-6731.
28. Bossola M., Muscaritoli M., Costelli P., Bellantone R., Pacelli F., Busquets S., et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1518-R1523.
29. DeJong C.H., Busquets S., Moses A.G., Schrauwen P., Ross J.A., Argiles J.M., et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep 2005, 14:257-263.
30. Gras F., Brunmair B., Quarre L., Szocs Z., Waldhausl W., Furnsinn C. Progesterone impairs cell respiration and suppresses a compensatory increase in glucose transport in isolated rat skeletal muscle: a non-genomic mechanism contributing to metabolic adaptation to late pregnancy?. Diabetologia 2007, 50:2544-2552.
31. Browning J.D., MacDonald R.S., Thornton W.H., O'Dell B.L. Reduced food intake in zinc deficient rats is normalized by megestrol acetate but not by insulin-like growth factor-I. J Nutr 1998, 128:136-142.
32. Mantovani G., Maccio A., Madeddu C., Gramignano G., Serpe R., Massa E., et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008, 24:305-313.
33. Mantovani G., Maccio A., Lai P., Massa E., Ghiani M., Santona M.C. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 1998, 9:99-106.
34. Argiles J.M., Busquets S., Toledo M., Lopez-Soriano F.J. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009, 3:263-268.
35. Stephens N.A., Skipworth R.J., Fearon K.C. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care 2008, 2:267-274.
36. Oster M.H., Enders S.R., Samuels S.J., Cone L.A., Hooton T.M., Browder H.P., et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994, 121:400-408.
37. Schmoll E., Wilke H., Thole R., Preusser P., Wildfang I., Schmoll H.J. Megestrol acetate in cancer cachexia. Semin Oncol 1991, 18:32-34.
38. Berenstein E.G., Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005, [CD004310].
39. Madeddu C., Maccio A., Panzone F., Tanca F.M., Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother 2009, 10:1359-1366.